Developed The First and Only 3D-Vector ECG Platform for Heart Attack Detection Anytime, Anywhere. 

Two Patented Products in Development: 3-D Software for Acute Care Settings and Credit Card Sized ECG Smart Phone App Device for Remote Detection. 

Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System.

Partnered with Evolve Manufacturing for 3D Vector Electrocardiogram Device. 

Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, Projected Within 2023.  

Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform. 

$25 Million Capital Raise to Support Funding of Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024. 

HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the BEAT platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. More than 18 million people in the US have Coronary Artery Disease. Every 40 seconds someone in the US has a heart attack, or myocardial infarction.  

BEAT has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. The BEAT HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. 

$25 Million Capital Raise Plus 2023 Strategic Focus and Financial Guidance

On May 3rd BEAT announced closing of a secondary offering of 16,666,666 shares of its common stock. This financing will allow BEAT to fund its upcoming clinical and regulatory milestones related to its HeartBeam AIMIGo™ system and prepare for commercialization in 2024.

BEAT received net proceeds of $23.2 million from the offering, after deducting the placement agent discounts and commissions and offering expenses. 

BEAT has adjusted its strategic focus to enable timely delivery of its breakthrough ambulatory VECG products, the Company’s key future value drivers, as follows:

Immediately focus on obtaining an FDA 510(k) clearance for the HeartBeam AIMIGo credit card- sized VECG device, followed by a second 510(k) clearance on the system’s ability to synthesize an electrocardiogram (ECG). The goal of this second FDA clearance is to demonstrate that the BEAT synthesized 12-lead ECG is equivalent to standard recorded 12-lead ECGs. These clearances provide a key value creation path, as they will enable physicians to remotely monitor patients and immediately interpret any concerning cardiac events.

Demonstrate through clinical trials in 2023 the performance of the HeartBeam AIMIGo platform, which BEAT management believes is the most advanced ambulatory cardiac detection platform available. BEAT believes this will drive clinical and patient adoption.

Shift the commercial launch until obtaining the 510(k) clearance for 12-lead equivalence. BEAT plans to submit this application to the FDA in late 2023 and pursue initial commercialization in 2024.

Undertake an aggressive pre-commercial effort to define initial market segments and identify potential business partners.

Continue aggressive development of its intellectual property through our partnership with PatentVest, a unified technology development and patent law firm focused on creating IP leadership for development stage technology companies. The partnership is clearly focused on the goal of creating clear leadership in the area of ambulatory VECG cardiac detection.

Add world leading Key Opinion Leaders (KOLs) to the Company’s Medical Advisory Board to help guide BEAT clinical and regulatory development. 

BEAT will hold a conference call to discuss the financing and the strategic initiatives, along with our first quarter 2023 financial results on May 11th. 

To access the call, use the following information:

Date: Thursday May 11, 2023

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Dial-in: 1-844-826-3035

International Dial-in: 1-412-317-5195

Conference Code: 10178249

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1611445&tp_key=13a316a5f0

A telephone replay will be available approximately two hours after the call and will run through August 11, 2023, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10178249. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the company’s investor relations section here: https://www.otcmarkets.com/stock/BEAT/news/story?e&id=2516338

For more information on BEAT visit www.HeartBeam.com

DISCLAIMER:

CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Media Contact
Company Name: HeartBeam, Inc.
Contact Person: Branislav Vajdic, PhD, CEO
Email: Send Email
Phone: (408) 899-4443
Address:2118 Walsh Avenue Suite 210
City: Santa Clara
State: CA 95050
Country: United States
Website: www.HeartBeam.com